Radiotherapy for glioblastoma patients with poor performance status
Open Access
- 26 August 2021
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (8) , 2127-2136
Abstract
Purpose: There is limited information on treatment recommendations for glioblastoma patients with poor performance status. Here, we aim to evaluate the association of radiotherapy on survival in glioblastoma patients presenting with poor postoperative performance status in first-line setting. Methods: We retrospectively analyzed data of 93 glioblastoma patients presenting with poor postoperative performance status (ECOG 2–4) at the University Hospital Zurich, Switzerland, in the years 2005–2019. A total of 43 patients received radiotherapy with or without systemic therapy in the first-line setting, whereas 50 patients received no additive local or systemic treatment after initial biopsy or resection. Overall survival was calculated from primary diagnosis and from the end of radiotherapy. In addition, factors influencing survival were analyzed. Results: Median overall survival from primary diagnosis was 6.2 months in the radiotherapy group (95% CI 6.2–14.8 weeks, range 2–149 weeks) and 2.3 months in the group without additive treatment (95% CI 1.3–7.4 weeks, range 0–28 weeks) (p < 0.001). This survival benefit was confirmed by landmark analyses. Factors associated with overall survival were extent of resection and administration of radiotherapy with or without systemic treatment. Median survival from end of radiotherapy was 3 months (95% CI 4.3–21.7 weeks, range 0–72 weeks), with 25.6% (n = 11) early termination of treatment and 83.7% (n = 36) requiring radiotherapy as in-patients. Performance status improved in 27.9% (n = 12) of patients after radiotherapy. Conclusion: In this retrospective single-institution analysis, radiotherapy improved overall survival in patients with poor performance status, especially in patients who were amendable to neurosurgical resection.Keywords
Funding Information
- Filling-The-Gap program (no number)
- Universität Zürich
This publication has 29 references indexed in Scilit:
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trialThe Lancet Oncology, 2012
- The Risk of Getting Worse: Surgically Acquired Deficits, Perioperative Complications, and Functional Outcomes After Primary Resection of GlioblastomaWorld Neurosurgery, 2011
- Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for GlioblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institutionJournal of Neurosurgery, 2011
- Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004Neuro-Oncology, 2010
- Radiotherapy for Glioblastoma in the ElderlyNew England Journal of Medicine, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical TrialJournal of Clinical Oncology, 2004
- Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome ProjectJournal of Neurosurgery, 2003
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI: Journal of the National Cancer Institute, 1993